At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 444 enrolled
Drug / intervention
MK-3475 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)
In Brief
A Phase 2 clinical trial evaluating MK-3475 and INCB024360 for Microsatellite-instability (MSI) High Colorectal Cancer (CRC) and 13 related conditions. Completed, enrolled 444 participants across 24 sites.
Detailed Summary
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMicrosatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC)
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartJul 2014
Primary CompletionNov 2018
Study CompletionNov 2020
TodayJul 2026
First PostedJul 1, 2014
Enrollment StartJul 17, 2014
Primary CompletionNov 26, 2018
Study CompletionNov 6, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 12.0 years ago
Interventions
MK-3475drug
IV infusion
INCB024360drug
Oral daily dosing